2. Protein Tyrosine Kinase/RTK
  3. c-Fms
  4. Anti-Mouse GM-CSF Antibody (MP1-22E9)

Anti-Mouse GM-CSF Antibody (MP1-22E9) 

Cat. No.: HY-P99134 Purity: 95.00%
COA
SDS
Technical Support

Anti-Mouse GM-CSF Antibody (MP1-22E9) is a rat-derived anti-mouse GM-CSF IgG2a antibody inhibitor. Anti-Mouse GM-CSF Antibody (MP1-22E9) can neutralize GM-CSF. Anti-Mouse GM-CSF Antibody (MP1-22E9) can be used for the researches of cancer, infection inflammation and immunology, such as cholangiocarcinoma and arthritis.

For research use only. We do not sell to patients.

Anti-Mouse GM-CSF Antibody (MP1-22E9) Chemical Structure

Anti-Mouse GM-CSF Antibody (MP1-22E9) Chemical Structure

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Anti-Mouse GM-CSF Antibody (MP1-22E9) Featured Recommendations:

Anti-Mouse GM-CSF Antibody (MP1-22E9) Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anti-Mouse GM-CSF Antibody (MP1-22E9) is a rat-derived anti-mouse GM-CSF IgG2a antibody inhibitor. Anti-Mouse GM-CSF Antibody (MP1-22E9) can neutralize GM-CSF. Anti-Mouse GM-CSF Antibody (MP1-22E9) can be used for the researches of cancer, infection inflammation and immunology, such as cholangiocarcinoma and arthritis[1][2][3][4][5][6].

Isotype

Rat IgG2a kappa
Recommend Isotype Controls
IC50 & Target

GM-CSF
In Vitro

Anti-Mouse GM-CSF Antibody (MP1-22E9) (72 h) significantly reduces macrophage viability in bone marrow -derived macrophages[1].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (10 μg/mL, 30 mins) promotes differentiation and migration in myeloid-derived suppressor cells[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse GM-CSF Antibody (MP1-22E9) Related Antibodies
In Vivo

Anti-Mouse GM-CSF Antibody (MP1-22E9) (30 mg/kg, i.p., every 2days for 4 week) inhibits progression of tumor and extended survival in autochthonous intrahepatic cholangiocarcinoma mice models[1].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (800 μg, i.p., every monday and thursday for 2 weeks) decreases angiogenesis in L2/IKKβca mice[2].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (250 μg, i.p., at the day before curdlan injection and twice weekly for 7 weeks or 9 days after disease triggering and twice weekly until day 28) inhibits bone marrow myelopoiesis and organ inflammation in spondyloarthritis mice models[3].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (200 μg, i.p., every 3 days) inhibits antitumor immunity by neutralizing GM-CSF in B16F10-OVA tumor-bearing mice models[4].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (100 μg, i.p., twice a week) shows anti-tumor effect in HM-1 tumor mice models[5].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (250 μg, i.p., every other day beginning one day prior to infection for 3 times) shows anti-infection effect in clostridium difficile infected mice models[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Autochthonous intrahepatic cholangiocarcinoma mice models[1]
Dosage: 30 mg/kg
Administration: Intraperitoneally injection, every 2days for 4 weeks
Result: Suppressed tumor growth and increased latency to the development of multifocal liver tumours.
Significant reduced TAM infiltration and expression of ARG1 and PD-L1.
Significantly reduced circulating monocytes in the blood and elevated numbers of BM granulocytes.
Significantly reduced CFU in BM mononuclear cells and splenocytes.
Animal Model: L2/IKKβca mice[2]
Dosage: 800 μg
Administration: Intraperitoneally injection, every monday and thursday for 2 weeks
Result: Reduced the number of CD31+ blood vessels and VWF positive endothelial cells.
Animal Model: Spondyloarthritis mice models[3]
Dosage: 250 μg
Administration: Intraperitoneally injection, at the day before curdlan injection and twice weekly for 7 weeks or 9 days after disease triggering and twice weekly until day 28
Result: Decrease in LT-HSCs, MPPs and GMPs in the BM and increased CLPs cells.
Reducecd neutrophils and increased erythroid cells and B cells.
Decreased intestinal and articular neutrophil invasion.
Showed significant ameliorations in the histological and clinical scores of arthritis, marked decreases in enthesitis-associated ankle thickening and new bone formation, and inhibition of the bone surface:volume ratio increase.
Showed significant amelioration in enteritis and weight loss.
Animal Model: B16F10-OVA tumor-bearing mice models[4]
Dosage: 200 μg
Administration: Intraperitoneally injection, every 3 days
Result: Reduced the IL9-inducing capacity of moDCs and cDCs.
Increased or unaffected s IFNγ induction from naive or total CD4+ T cells.
Animal Model: HM-1 tumor mice models[5]
Dosage: 100 μg/mouse
Administration: Intraperitoneally injection, twice a week
Result: Suppressed tumor growth.
Decreased MDSCs.
Enhanced the efficacy of anti-VEGF abs.
Animal Model: Clostridium difficile infected mice models[6]
Dosage: 250 μg/mouse
Administration: Intraperitoneally injection, every other day beginning one day prior to infection for 3 times
Result: Showed lower C. difficile colonization levels and more modest weight loss.
Reduced IL-22 levels.
Resulted in significantly lower expression of IL-1β and TNFα.
Significantly reduced expression of the ELR+ CXC chemokines CXCL1 (KC) and CXCL2 (MIP-2).
Reduced neutrophils t in colonic mucosal sections and decreased iNOS expression.
Gene ID

12981  [NCBI]

Accession
Application

ELISA, FACS, Functional assay, Research in vivo
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

150 kDa

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Anti-Mouse GM-CSF Antibody (MP1-22E9)]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anti-Mouse GM-CSF Antibody (MP1-22E9) Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anti-Mouse GM-CSF Antibody (MP1-22E9)c-FmsCSF-1 receptorcolony stimulating factor 1 receptorCSF-1RCSF1RGM-CSFCancerCholangiocarcinomaArthritisB16F10-OVAHM-1Clostridium difficileInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anti-Mouse GM-CSF Antibody (MP1-22E9)
Cat. No.:
HY-P99134
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.